SEPARATION AND RELEASE OF CLAIMS AGREEMENTSeparation and Release of Claims Agreement • April 17th, 2023 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This SEPARATION AND RELEASE OF CLAIMS AGREEMENT (the “Agreement”) is made as of the Agreement Effective Date (as defined below) between Nabriva Therapeutics US, Inc. (the “Company”) and Christine Guico-Pabia (“Executive”) (together, the “Parties”).
NABRIVA THERAPEUTICS US, INC. CONSULTING AGREEMENTConsulting Agreement • April 17th, 2023 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This Consulting Agreement (“Agreement”) is effective as of February 1, 2023 (the “Effective Date”) by and between Nabriva Therapeutics US, Inc., a Delaware corporation, with a business address of 414 Commerce Drive, Suite 120, Fort Washington PA 19304 (“Company”), and Christine Guico-Pabia having an address at [**] (“Consultant”).
THIRD AMENDMENT to API SUPPLY AGREEMENTApi Supply Agreement • April 17th, 2023 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS THIRD AMENDMENT (“Amendment”) is entered into by and between Nabriva Therapeutics Ireland DAC, with a principal place of business at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland (“Nabriva”), and Hovione Limited, (“Hovione”). All capitalized terms not defined in this Amendment shall have the same meaning as set forth in the Agreement (defined below).
